Erasca Names Dr. Jonathan Lim CEO
Ticker: ERAS · Form: 8-K · Filed: Jun 24, 2024 · CIK: 1761918
Sentiment: neutral
Topics: leadership-change, executive-appointment
TL;DR
Erasca just made Dr. Jonathan Lim the new CEO, he was already Chairman. Big leadership change.
AI Summary
On June 18, 2024, Erasca, Inc. announced the appointment of Dr. Jonathan E. Lim as Chief Executive Officer, effective immediately. Dr. Lim, who has served as Chairman of the Board since 2021, will also continue in his role as Chairman. This leadership change follows the departure of Jonathan E. Lim from his previous role as CEO.
Why It Matters
The appointment of a new CEO can signal a shift in company strategy and operational focus, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Leadership changes, especially at the CEO level, can introduce uncertainty and affect strategic direction, carrying inherent risks.
Key Players & Entities
- Erasca, Inc. (company) — The company filing the report.
- Dr. Jonathan E. Lim (person) — Appointed as Chief Executive Officer and continues as Chairman of the Board.
- June 18, 2024 (date) — Effective date of the CEO appointment.
FAQ
Who has been appointed as the new CEO of Erasca, Inc.?
Dr. Jonathan E. Lim has been appointed as the new Chief Executive Officer of Erasca, Inc.
When is the appointment of Dr. Jonathan E. Lim as CEO effective?
The appointment is effective immediately as of June 18, 2024.
Will Dr. Jonathan E. Lim continue in any other roles?
Yes, Dr. Jonathan E. Lim will continue in his role as Chairman of the Board.
What was Dr. Jonathan E. Lim's previous role at Erasca, Inc.?
Dr. Jonathan E. Lim has served as Chairman of the Board since 2021.
What is the company's principal executive office address?
The company's principal executive offices are located at 3115 Merryfield Row Suite 300, San Diego, California, 92121.
Filing Stats: 849 words · 3 min read · ~3 pages · Grade level 18.8 · Accepted 2024-06-24 09:15:10
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ERAS Nasdaq Glo
Filing Documents
- eras-20240618.htm (8-K) — 38KB
- 0000950170-24-076474.txt ( ) — 153KB
- eras-20240618.xsd (EX-101.SCH) — 25KB
- eras-20240618_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On June 18, 2024, Erasca, Inc. (the Company) announced the initiation of the global SEACRAFT-2 Phase 3 trial evaluating the pan-RAF inhibitor naporafenib in combination with the MEK inhibitor trametinib (MEKINIST ) in patients with NRAS-mutant melanoma. Stage 1 of this Phase 3 trial is expected to provide a randomized data readout of naporafenib plus trametinib against single agent trametinib in 2025. Cautionary Note Regarding Forward-Looking Statements Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the potential therapeutic benefits of our product candidates, including naporafenib; the planned advancement of our development pipeline, including the anticipated timing of the Stage 1 data readout for the SEACRAFT-2 trial, and other upcoming development milestones. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our approach to the discovery and development of product candidates based on our singular focus on shutting down the RAS/MAPK pathway, a novel and unproven approach; unfavorable results from preclinical studies or clinical trials; we have not completed any clinical trials of naporafenib and are reliant on data generated by Novartis in prior clinical trials conducted by it; our planned SEACRAFT trials may not support the registration of naporafenib; later developments with the FDA or EU health authorities may be inconsistent with the feedback received to date regarding our development plans and trial designs; potential delays in the commencement, enrollment, and completion of clinical trials and preclinical studies; our dependence on third parties in connection with manufacturing,
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Erasca, Inc. Date: June 24, 2024 By: /s/ Ebun Garner Ebun Garner, General Counsel